Stock ATHE ALTERITY THERAPEUTICS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Alterity Therapeutics Limited Nasdaq

Equities

ATHE

US02155X2053

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 16:30:00 2024-05-17 EDT 		5-day change 1st Jan Change
2 USD -0.99% Intraday chart for Alterity Therapeutics Limited -0.50% -19.68%
05-08 Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review CI
05-08 Alterity Therapeutics on Track to Complete Phase Two Trial of Lead Drug Candidate in November MT

Valuation

Fiscal Period: June 2021 2022 2023 2024 2025 2026
Capitalization 1 43.75 21.58 11.37 17.53 - -
Enterprise Value (EV) 2 43.75 21.58 11.37 14.42 10.91 11.11
P/E ratio - - - - - -
Yield - - - - - -
Capitalization / Revenue 13.3 x 6.12 x 4.45 x 6.79 x 4.64 x 6.02 x
EV / Revenue 13.3 x 6.12 x 4.45 x 5.58 x 2.89 x 3.81 x
EV / EBITDA - - - -1.13 x -0.9 x -0.83 x
EV / FCF - -2.53 x - -1.27 x -1.98 x -84.1 x
FCF Yield - -39.5% - -78.5% -50.4% -1.19%
Price to Book - - - - - -
Nbr of stocks (in thousands) 2,084,017 2,406,875 2,439,898 5,245,115 - -
Reference price 3 0.0280 0.0130 0.007000 0.005000 0.005000 0.005000
Announcement Date 8/31/21 8/31/22 8/31/23 - - -
1AUD in Million2USD in Million3
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: June 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - 3.292 3.528 2.554 2.582 3.774 2.914
EBITDA 1 - - - - -12.78 -12.18 -13.44
EBIT 1 - -10.75 -10.42 -9.321 -12.78 -11.2 -12.68
Operating Margin - -326.64% -295.25% -364.93% -494.97% -296.82% -435.07%
Earnings before Tax (EBT) 1 - -11.19 -8.795 -8.899 -8.841 -10.37 -12.05
Net income 1 -7.395 -11.19 -8.843 -8.966 -12.65 -11.24 -12.71
Net margin - -339.76% -250.62% -351.06% -489.81% -297.87% -436.29%
EPS - - - - - - -
Free Cash Flow 1 - - -8.531 - -11.32 -5.496 -0.132
FCF margin - - -241.79% - -438.54% -145.62% -4.53%
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share - - - - - - -
Announcement Date 8/30/20 8/31/21 8/31/22 8/31/23 - - -
1USD in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: June 2021 S1 2021 S2 2022 S1 2022 S2 2023 S1 2023 S2 2024 S1 2024 S2
Net sales 1 - 1.881 - 1.904 1.619 - 1.313 0.9096
EBITDA - - - - - - - -
EBIT 1 - -5.238 - -5.189 -5.549 -3.983 -4.166 -4.446
Operating Margin - -278.4% - -272.59% -342.82% - -317.31% -488.85%
Earnings before Tax (EBT) 1 - -4.93 - -4.263 -5.354 - -4.232 -4.521
Net income 1 -6.815 -4.93 -4.779 -4.311 -5.424 - -4.232 -4.521
Net margin - -262.04% - -226.49% -335.05% - -322.28% -497.03%
EPS - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 2/25/21 8/31/21 2/28/22 8/31/22 2/28/23 8/31/23 2/29/24 -
1USD in Million
Estimates

Balance Sheet Analysis

Fiscal Period: June 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - -
Net Cash position 1 - - - - 3.11 6.62 6.42
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow 1 - - -8.53 - -11.3 -5.5 -0.13
ROE (net income / shareholders' equity) - - - - - - -
ROA (Net income/ Total Assets) - - - - - - -
Assets 1 - - - - - - -
Book Value Per Share - - - - - - -
Cash Flow per Share - - - - - - -
Capex 1 - 0.01 0.06 - - - -
Capex / Sales - 0.23% 1.73% - - - -
Announcement Date 8/30/20 8/31/21 8/31/22 8/31/23 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MODERNA, INC. Stock Moderna, Inc.
+33.63% 50.85B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-0.09% 42.82B
LONZA GROUP AG Stock Lonza Group AG
+49.62% 42.03B
CELLTRION, INC. Stock Celltrion, Inc.
-4.96% 29.55B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.18% 26.11B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.95% 19.13B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+8.61% 13.05B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+28.31% 12.16B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+24.73% 12.08B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ATH Stock
  4. ATHE Stock
  5. Financials Alterity Therapeutics Limited
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW